Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles

Open access
B. Shekhawat, Prachi, B. Pokharkar, Varsha·2017·Acta Pharmaceutica Sinica B

Abstract

Oral drug absorption is a process influenced by the physicochemical and biopharmaceutical properties of the drug and its inter-relationship with the gastrointestinal tract. Drug solubility, dissolution and permeability across intestinal barrier are the key parameters controlling absorption. This review provides an overview of the factors that affect drug absorption and the classification of a drug on the basis of solubility and permeability. The biopharmaceutical classification system (BCS) was introduced in early 90׳s and is a regulatory tool used to predict bioavailability problems associated with a new entity, thereby helping in the development of a drug product. Strategies to combat solubility and permeability issues are also discussed. Bioavailability of a drug depends on physicochemical properties of the drug and physiological factors and dosage-related factors. Drug absorption occurs from the gut wall by passive diffusion, carrier-mediated uptake and paracellular transport. Several formulation strategies can be used to combat poor bioavailability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2016.09.005

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 156

  1. Bergström, 2014, Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs, Eur J Pharm Sci, 57, 173, 10.1016/j.ejps.2013.10.015 · DOI · Paper page
  2. Dokoumetzidis, 2006, A century of dissolution research: from noyes and whitney to the biopharmaceutics classification system, Int J Pharm, 321, 1, 10.1016/j.ijpharm.2006.07.011 · DOI · Paper page
  3. Noyes, 1897, The rate of solution of solid substances in their own solutions, J Am Chem Soc, 19, 930, 10.1021/ja02086a003 · DOI · Paper page
  4. Brünner, 1904, Reaktionsgeschwindigkeit in heterogen systemen, Z Phys Chem, 47, 56, 10.1515/zpch-1904-4705 · DOI · Paper page
  5. Hixson, 1931, Dependence of reaction velocity upon surface and agitation, Ind Eng Chem, 23, 923, 10.1021/ie50260a018 · DOI · Paper page
  6. Danckwerts, 1951, Significance of liquid-film coefficients in gas absorption, Ind Eng Chem, 43, 1460, 10.1021/ie50498a055 · DOI · Paper page
  7. Higuchi, 1961, Rate of release of medicaments from ointment bases containing drugs in suspension, J Pharm Sci, 50, 874, 10.1002/jps.2600501018 · DOI · Paper page
  8. Brown, 2014, USP and dissolution—20 years of progress, Dissolut Technol, 2014, 24, 10.14227/DT210314P24 · doi:10.14227/dt210314p24
  9. Federation International Pharmaceutique, 1981, FIP guidelines for dissolution testing of solid oral products, Die Pharm Ind, 42, 334
  10. Dahan, 2009, Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs, AAPS J, 11, 740, 10.1208/s12248-009-9144-x · DOI · Paper page
  11. Martinez, 2002, A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals, J Clin Pharmacol, 42, 620, 10.1177/00970002042006005 · DOI · Paper page
  12. Pavurala, 2013, A mechanistic approach for modeling oral drug delivery, Comp Chem Eng, 57, 196, 10.1016/j.compchemeng.2013.06.002 · DOI
  13. Lennernäs, 1998, Human intestinal permeability, J Pharm Sci, 87, 403, 10.1021/js970332a · DOI · Paper page
  14. Yu, 1996, Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption, Adv Drug Deliv Rev, 19, 359, 10.1016/0169-409X(96)00009-9 · DOI · Paper page
  15. Azarmi, 2007, Current perspectives in dissolution testing of conventional and novel dosage forms, Int J Pharm, 328, 12, 10.1016/j.ijpharm.2006.10.001 · DOI · Paper page
  16. Alsenz, 2007, High throughput solubility measurement in drug discovery and development, Adv Drug Deliv Rev, 59, 546, 10.1016/j.addr.2007.05.007 · DOI · Paper page
  17. Noyes, 1987, The rate of solution of solid substances in their own solutions, J Am Chem Soc, 19, 930, 10.1021/ja02086a003 · DOI · Paper page
  18. Bansil, 2006, Mucin structure, aggregation, physiological functions and biomedical applications, Curr Opin Colloid Interface Sci, 11, 164, 10.1016/j.cocis.2005.11.001 · DOI · Paper page
  19. Behrens, 2001, Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells, Pharm Res, 18, 1138, 10.1023/A:1010974909998 · DOI · Paper page
  20. Smith, 1999, Pharmacokinetics and metabolism in early drug discovery, Curr Opin Chem Biol, 3, 373, 10.1016/S1367-5931(99)80056-8 · DOI · Paper page
  21. Lipka, 1996, Transmembrane transport of peptide type compounds: prospects for oral delivery, J Control Release, 39, 121, 10.1016/0168-3659(95)00145-X · doi:10.1016/0168-3659(95)00145-x
  22. Petri, 2006, Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers, Int J Clin Pharmacol Ther, 44, 71, 10.5414/CPP44071 · DOI
  23. Estudante, 2013, Intestinal drug transporters: an overview, Adv Drug Deliv Rev, 65, 1340, 10.1016/j.addr.2012.09.042 · DOI · Paper page
  24. Minuesa, 2011, Drug uptake transporters in antiretroviral therapy, Pharm Ther, 132, 268, 10.1016/j.pharmthera.2011.06.007 · DOI
  25. Kunta, 2004, Intestinal drug transporters: in vivo function and clinical importance, Curr Drug Metab, 5, 109, 10.2174/1389200043489144 · DOI
  26. Varma, 2006, Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery, Curr Opin Chem Biol, 10, 367, 10.1016/j.cbpa.2006.06.015 · DOI
  27. Curatolo, 1998, Physical chemical properties of oral drug candidates in the discovery and exploratory development settings, Pharm Sci Technol Today, 1, 387, 10.1016/S1461-5347(98)00097-2 · doi:10.1016/s1461-5347(98)00097-2
  28. Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J Pharmacol Toxicol Methods, 44, 235, 10.1016/S1056-8719(00)00107-6 · DOI · Paper page
  29. van de Waterbeemd, 2001, Property-based design: optimization of drug absorption and pharmacokinetics, J Med Chem, 44, 1313, 10.1021/jm000407e · DOI · Paper page
  30. Lipinski, 2004, Navigating chemical space for biology and medicine, Nature, 432, 855, 10.1038/nature03193 · DOI · Paper page
  31. Wenlock, 2003, A comparison of physiochemical property profiles of development and marketed oral drugs, J Med Chem, 46, 1250, 10.1021/jm021053p · DOI · Paper page
  32. Palm, 1997, Polar molecular surface properties predict the intestinal absorption of drugs in humans, Pharm Res, 14, 568, 10.1023/A:1012188625088 · DOI · Paper page
  33. Clark, 1999, Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption, J Pharm Sci, 88, 807, 10.1021/js9804011 · DOI · Paper page
  34. Ritchie, 2009, The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design?, Drug Discov Today, 14, 1011, 10.1016/j.drudis.2009.07.014 · DOI · Paper page
  35. Dressman, 1985, Absorption potential: estimating the fraction absorbed for orally administered compounds, J Pharm Sci, 74, 588, 10.1002/jps.2600740523 · DOI · Paper page
  36. Yalkowsky, 2006, A ‘rule of unity’ for human intestinal absorption, Pharm Res, 23, 2475, 10.1007/s11095-006-9000-y · doi:10.1007/s11095-006-9000-y
  37. Fleisher, 1999, Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications, Clin Pharmacokinet, 36, 233, 10.2165/00003088-199936030-00004 · DOI · Paper page
  38. Freire, 2011, Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery, Int J Pharm, 415, 15, 10.1016/j.ijpharm.2011.04.069 · DOI · Paper page
  39. Avdeef, 2001, Physicochemical profiling (solubility, permeability and charge state), Curr Top Med Chem, 1, 277, 10.2174/1568026013395100 · DOI · Paper page
  40. Kimura, 2002, Gastrointestinal transit and drug absorption, Biol Pharm Bull, 25, 149, 10.1248/bpb.25.149 · DOI · Paper page
  41. Fujioka, 2008, Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug, Int J Pharm, 352, 36, 10.1016/j.ijpharm.2007.10.008 · DOI
  42. Cook, 2002, An industrial implementation of the biopharmaceutics classification system, Dissolut Technol, 9, 6, 10.14227/DT090202P6 · doi:10.14227/dt090202p6
  43. Cook, 2010, Impact of biopharmaceutics classification system-based biowaivers, Mol Pharm, 7, 1539, 10.1021/mp1001747 · DOI
  44. Sakore, 2011, In vitro–in vivo correlation (IVIVC): a strategic tool in drug development, J Bioequiv Availab, 2011, S3
  45. Batchelor, 2013, Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients, Eur J Pharm Biopharm, 85, 833, 10.1016/j.ejpb.2013.04.015 · DOI
  46. Alelyunas, 2009, Application of a dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates, Eur J Pharm Sci, 37, 172, 10.1016/j.ejps.2009.02.007 · DOI
  47. Saal, 2012, Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks, Eur J Pharm Sci, 47, 589, 10.1016/j.ejps.2012.07.019 · DOI
  48. Zhou, 2007, Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery, J Pharm Sci, 96, 3052, 10.1002/jps.20913 · DOI
  49. Hörter, 1997, Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv Drug Deliv Rev, 25, 3, 10.1016/S0169-409X(96)00487-5 · DOI · Paper page
  50. Lue, 2008, Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound, Eur J Pharm Biopharm, 69, 648, 10.1016/j.ejpb.2007.12.013 · DOI
  51. Klein, 2010, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS J, 12, 397, 10.1208/s12248-010-9203-3 · DOI · Paper page
  52. Aiache, 1997, FIP guidelines for dissolution testing of solid oral products, Dissolut Technol, 4, 5, 10.14227/DT040497P5 · DOI
  53. Wei, 2006, Biorelevant dissolution media as a predictive tool for glyburide a class II drug, Eur J Pharm Sci, 29, 45, 10.1016/j.ejps.2006.05.004 · DOI
  54. Lehto, 2011, Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs, Eur J Pharm Biopharm, 78, 531, 10.1016/j.ejpb.2011.02.007 · DOI
  55. Tsume, 2013, Dissolution effect of gastric and intestinal pH fora BCS class II drug, pioglitazone: new in vitro dissolution system to predict in vivo dissolution, J Bioequiv Availab, 5, 224, 10.4172/jbb.1000162 · doi:10.4172/jbb.1000162
  56. Motz, 2007, Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell, Eur J Pharm Biopharm, 66, 286, 10.1016/j.ejpb.2006.10.015 · DOI
  57. Zakeri-Milani, 2009, Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability, Eur J Pharm Biopharm, 73, 102, 10.1016/j.ejpb.2009.04.015 · DOI
  58. Muenster, 2011, Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions, Eur J Pharm Biopharm, 78, 522, 10.1016/j.ejpb.2011.01.023 · DOI
  59. Lennernäs, 2014, Human in vivo regional intestinal permeability: importance for pharmaceutical drug development, Mol Pharm, 11, 12, 10.1021/mp4003392 · DOI
  60. Lennernäs, 2013, Regional intestinal drug permeation: biopharmaceutics and drug development, Eur J Pharm Sci, 57, 333, 10.1016/j.ejps.2013.08.025 · DOI · Paper page
  61. Wahlang, 2011, Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model, Eur J Pharm Biopharm, 77, 275, 10.1016/j.ejpb.2010.12.006 · DOI · Paper page
  62. Blume, 1999, The biopharmaceutics classification system (BCS): class III drugs—better candidates for BA/BE waiver?, Eur J Pharm Sci, 9, 117, 10.1016/S0928-0987(99)00076-7 · DOI
  63. Tsume, 2014, The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC, Eur J Pharm Sci, 57, 152, 10.1016/j.ejps.2014.01.009 · DOI · Paper page
  64. Custodio, 2008, Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption, Adv Drug Deliv Rev, 60, 717, 10.1016/j.addr.2007.08.043 · DOI · Paper page
  65. Shah, 2011, Recent advances and novel strategies in pre-clinical formulation development: an overview, J Control Release, 156, 281, 10.1016/j.jconrel.2011.07.003 · DOI
  66. Rabinow, 2004, Nanosuspensions in drug delivery, Nat Rev Drug Discov, 3, 785, 10.1038/nrd1494 · DOI · Paper page
  67. Basavaraj, 2014, Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges, Acta Pharm Sin B, 4, 3, 10.1016/j.apsb.2013.12.003 · DOI
  68. Desai, 2012, Overcoming poor oral bioavailability using nanoparticle formulations—opportunities and limitations, Drug Discov Today, 9, e87, 10.1016/j.ddtec.2011.12.001 · DOI · Paper page
  69. Huang, 2014, Fundamental aspects of solid dispersion technology for poorly soluble drugs, Acta Pharm Sin B, 4, 18, 10.1016/j.apsb.2013.11.001 · DOI · Paper page
  70. Vo, 2013, Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs, Eur J Pharm Biopharm, 85, 799, 10.1016/j.ejpb.2013.09.007 · DOI · Paper page
  71. Blagden, 2007, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv Drug Deliv Rev, 59, 617, 10.1016/j.addr.2007.05.011 · DOI · Paper page
  72. Elder, 2013, Use of pharmaceutical salts and cocrystals to address the issue of poor solubility, Int J Pharm, 453, 88, 10.1016/j.ijpharm.2012.11.028 · doi:10.1016/j.ijpharm.2012.11.028
  73. Semalty, 2014, Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: a critical and meta-analysis, Expert Opin Drug Deliv, 11, 1255, 10.1517/17425247.2014.916271 · DOI
  74. Brewster, 2007, Cyclodextrins as pharmaceutical solubilizers, Adv Drug Deliv Rev, 59, 645, 10.1016/j.addr.2007.05.012 · DOI · Paper page
  75. Mu, 2013, Lipid-based formulations for oral administration of poorly water-soluble drugs, Int J Pharm, 453, 215, 10.1016/j.ijpharm.2013.03.054 · DOI · Paper page
  76. Chen, 2011, Nanonization strategies for poorly water-soluble drugs, Drug Discov Today, 16, 354, 10.1016/j.drudis.2010.02.009 · DOI · Paper page
  77. Dinarvand, 2015, Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer, Int J Biol Macromol, 78, 112, 10.1016/j.ijbiomac.2015.03.066 · doi:10.1016/j.ijbiomac.2015.03.066
  78. Kharia, 2015, Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach, J Microencapsul, 32, 521, 10.3109/02652048.2015.1010457 · doi:10.3109/02652048.2015.1010457
  79. Sharma, 2015, Investigating the role of pluronic-g-cationic polyelectrolyte as functional stabilizer for nanocrystals: impact on paclitaxel oral bioavailability and tumor growth, Acta Biomater, 26, 169, 10.1016/j.actbio.2015.08.005 · DOI
  80. Gadadare, 2015, Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior, AAPS PharmSciTech, 16, 787, 10.1208/s12249-014-0267-8 · DOI
  81. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv Drug Deliv Rev, 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
  82. Durán-Lobato, 2014, Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles, J Biomed Nanotechnol, 10, 1068, 10.1166/jbn.2014.1806 · DOI
  83. Chellampillai, 2011, Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles, Eur J Drug Metab Pharmacokinet, 35, 123, 10.1007/s13318-010-0016-7 · DOI
  84. Cho, 2010, Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives, Int J Pharm, 396, 91, 10.1016/j.ijpharm.2010.06.016 · doi:10.1016/j.ijpharm.2010.06.016
  85. Dalvi, 2013, Precipitation and stabilization of ultrafine particles of Fenofibrate in aqueous suspensions by RESOLV, Powder Technol, 236, 75, 10.1016/j.powtec.2012.05.038 · DOI
  86. Bege, 2013, In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm, Eur J Pharm Biopharm, 84, 99, 10.1016/j.ejpb.2012.12.016 · doi:10.1016/j.ejpb.2012.12.016
  87. Zhang, 2013, Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement, Eur J Pharm Sci, 48, 740, 10.1016/j.ejps.2012.12.026 · doi:10.1016/j.ejps.2012.12.026
  88. Angi, 2014, Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties, Eur J Pharm Biopharm, 86, 361, 10.1016/j.ejpb.2013.10.004 · DOI
  89. Saremi, 2013, Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies, Biomed Res Int, 2013, 150478, 10.1155/2013/150478 · DOI
  90. Tam, 2015, AH. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery, Colloids Surf B Biointerfaces, 139, 249, 10.1016/j.colsurfb.2015.12.026 · DOI
  91. Liu, 2015, Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation, Int J Nanomed, 10, 6425, 10.2147/IJN.S87143 · DOI
  92. Ahuja, 2015, Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension, Int J Pharm, 478, 540, 10.1016/j.ijpharm.2014.12.003 · DOI
  93. Quan, 2012, A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability, Int J Pharm, 430, 366, 10.1016/j.ijpharm.2012.04.025 · doi:10.1016/j.ijpharm.2012.04.025
  94. Onoue, 2013, In vitro/in vivo characterization of nanocrystalline formulation of tranilast with improved dissolution and hepatoprotective properties, Eur J Pharm Biopharm, 85, 952, 10.1016/j.ejpb.2013.09.003 · doi:10.1016/j.ejpb.2013.09.003
  95. Nkansah, 2013, Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs, J Control Release, 169, 150, 10.1016/j.jconrel.2013.03.032 · doi:10.1016/j.jconrel.2013.03.032
  96. Yoshida, 2012, Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: evaluation of solid dispersion formulations, Int J Pharm, 428, 18, 10.1016/j.ijpharm.2012.02.041 · DOI
  97. Choudhary, 2012, Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability, Acta Pharm Sin B, 2, 421, 10.1016/j.apsb.2012.05.002 · DOI
  98. Visser, 2010, Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240, Eur J Pharm Biopharm, 74, 233, 10.1016/j.ejpb.2009.10.004 · doi:10.1016/j.ejpb.2009.10.004
  99. Shi, 2013, Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions, Powder Technol, 247, 211, 10.1016/j.powtec.2013.06.039 · DOI
  100. Kawabata, 2010, Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability, Eur J Pharm Sci, 39, 256, 10.1016/j.ejps.2009.12.009 · DOI
  101. Mora, 2013, Characterization, dissolution and in vivo evaluation of solid acetazolamide complexes, Carbohydr Polym, 98, 380, 10.1016/j.carbpol.2013.06.012 · DOI
  102. Mennini, 2014, Physico-chemical characterization in solution and in the solid state of clonazepam complexes with native and chemically-modified cyclodextrins, J Pharm Biomed Anal, 89, 142, 10.1016/j.jpba.2013.11.009 · doi:10.1016/j.jpba.2013.11.009
  103. Salústio, 2012, Release profile of ibuprofen in β-cyclodextrin complexes from two different solid dosage forms, Powder Technol, 221, 245, 10.1016/j.powtec.2012.01.008 · doi:10.1016/j.powtec.2012.01.008
  104. Miao, 2016, Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state, Drug Dev Ind Pharm, 42, 1234, 10.3109/03639045.2015.1118496 · DOI
  105. Zhang, 2012, Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery, Int J Pharm, 427, 337, 10.1016/j.ijpharm.2012.02.013 · DOI
  106. Christiansen, 2014, Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano emulsifying drug delivery system (SNEDDS), Eur J Pharm Sci, 57, 164, 10.1016/j.ejps.2013.11.003 · DOI
  107. Elgart, 2013, Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol, Pharm Res, 30, 3029, 10.1007/s11095-013-1063-y · DOI
  108. Bajaj, 2013, Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate, Drug Dev Ind Pharm, 39, 635, 10.3109/03639045.2012.683440 · DOI
  109. Beg, 2012, Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers, AAPS PharmSciTech, 13, 1416, 10.1208/s12249-012-9865-5 · doi:10.1208/s12249-012-9865-5
  110. Miao, 2015, Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect, Drug Deliv, 21, 1
  111. Hyma, 2013, Formulation and characterisation of self-microemulsifying drug delivery system of pioglitazone, Biomed Prev Nutr, 3, 345, 10.1016/j.bionut.2013.09.005 · doi:10.1016/j.bionut.2013.09.005
  112. Kalhapure, 2012, Akamanchi. Oleic acid based heterolipid synthesis, characterization and application in self-microemulsifying drug delivery system, Int J Pharm, 425, 9, 10.1016/j.ijpharm.2012.01.004 · DOI
  113. Liu, 2012, Preparation and evaluation of self-microemulsifying drug delivery system of baicalein, Fitoterapia, 83, 1532, 10.1016/j.fitote.2012.08.021 · DOI
  114. Videira, 2013, Experimental design towards an optimal lipid nanosystem: a new opportunity for paclitaxel-based therapeutics, Eur J Pharm Sci, 49, 302, 10.1016/j.ejps.2013.03.005 · DOI
  115. Beloqui, 2013, Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier, J Control Release, 166, 115, 10.1016/j.jconrel.2012.12.021 · DOI · Paper page
  116. Sanganwar, 2008, Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide, Int J Pharm, 360, 213, 10.1016/j.ijpharm.2008.04.041 · DOI
  117. Ambrogi, 2012, MCM-41 for furosemide dissolution improvement, Microp Mesop Mater, 147, 343, 10.1016/j.micromeso.2011.07.007 · DOI
  118. Ambrogi, 2007, Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate, Eur J Pharm Sci, 32, 216, 10.1016/j.ejps.2007.07.005 · DOI
  119. Mellaerts, 2008, Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica, Eur J Pharm Biopharm, 69, 223, 10.1016/j.ejpb.2007.11.006 · DOI · Paper page
  120. Salonen, 2005, Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs, J Control Release, 108, 362, 10.1016/j.jconrel.2005.08.017 · DOI · Paper page
  121. Chen, 2015, Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles, Int J Nanomed, 10, 7265
  122. Dahmani, 2012, Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation, Eur J Pharm Sci, 47, 179, 10.1016/j.ejps.2012.05.015 · DOI
  123. Smith, 2011, Cocrystals of quercetin with improved solubility and oral bioavailability, Mol Pharm, 8, 1867, 10.1021/mp200209j · DOI · Paper page
  124. Basavoju, 2008, Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization, Pharm Res, 25, 530, 10.1007/s11095-007-9394-1 · doi:10.1007/s11095-007-9394-1
  125. Évora, 2014, A thermodynamic based approach on the investigation of a diflunisal pharmaceutical co-crystal with improved intrinsic dissolution rate, Int J Pharm, 466, 68, 10.1016/j.ijpharm.2014.02.048 · doi:10.1016/j.ijpharm.2014.02.048
  126. Soares, 2014, Evaluation of analytical tools and multivariate methods for quantification of co-former crystals in ibuprofen-nicotinamide co-crystals, J Pharm Biomed Anal, 89, 166, 10.1016/j.jpba.2013.11.005 · DOI
  127. Mulye, 2012, Improvement in physicochemical properties of ezetimibe using a crystal engineering technique, Powder Technol, 222, 131, 10.1016/j.powtec.2012.02.020 · doi:10.1016/j.powtec.2012.02.020
  128. Sadekar, 2013, Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin, Int J Pharm, 456, 175, 10.1016/j.ijpharm.2013.07.071 · DOI
  129. Gupta, 2007, Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes, J Pharm Pharm Sci, 10, 358
  130. Cheng, 2005, Polyamidoamine dendrimers used as solubility enhancers of ketoprofen, Eur J Med Chem, 40, 1390, 10.1016/j.ejmech.2005.08.002 · DOI
  131. Yáñez, 2011, Intestinal lymphatic transport for drug delivery, Adv Drug Deliv Rev, 63, 923, 10.1016/j.addr.2011.05.019 · DOI · Paper page
  132. Carrière, 2016, Impact of gastrointestinal lipolysis on oral lipid based formulations and bioavailability of lipophilic drugs, Biochimie, 125, 297, 10.1016/j.biochi.2015.11.016 · DOI
  133. Pouton, 2006, Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur J Pharm Sci, 29, 278, 10.1016/j.ejps.2006.04.016 · DOI · Paper page
  134. Kumar, 2011, Nonionic surfactant vesicular systems for effective drug delivery-an overview, Acta Pharm Sin B, 1, 208, 10.1016/j.apsb.2011.09.002 · DOI · Paper page
  135. Pandita, 2014, Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol, Food Res Int, 62, 1165, 10.1016/j.foodres.2014.05.059 · DOI · Paper page
  136. Das, 2011, Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech, 12, 62, 10.1208/s12249-010-9563-0 · DOI · Paper page
  137. Iqbal, 2012, Nanostructured lipid carriers system: recent advances in drug delivery, J Drug Target, 20, 813, 10.3109/1061186X.2012.716845 · DOI · Paper page
  138. Chiou, 1971, Pharmaceutical applications of solid dispersion systems, J Pharm Sci, 60, 1281, 10.1002/jps.2600600902 · DOI · Paper page
  139. van der Mooter, 2012, The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate, Drug Discov Today, 9, e79, 10.1016/j.ddtec.2011.10.002 · DOI · Paper page
  140. Good, 2009, Solubility advantage of pharmaceutical cocrystals, Cryst Growth Des, 9, 2252, 10.1021/cg801039j · DOI · Paper page
  141. Jayasankar, 2010, Transformation pathways of cocrystal hydrates when coformer modulates water activity, J Pharm Sci, 99, 3977, 10.1002/jps.22245 · doi:10.1002/jps.22245
  142. Sanphui, 2012, Pharmaceutical cocrystals of niclosamide, Cryst Growth Des, 12, 4588, 10.1021/cg300784v · DOI
  143. McNamara, 2006, Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharm Res, 23, 1888, 10.1007/s11095-006-9032-3 · DOI · Paper page
  144. Vig, 2013, Amino acids as promoieties in prodrug design and development, Adv Drug Deliv Rev, 65, 1370, 10.1016/j.addr.2012.10.001 · DOI
  145. Rodriguez-Aller, 2013, In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application, J Control Release, 170, 153, 10.1016/j.jconrel.2013.04.019 · DOI
  146. Li, 2014, A macromolecular prodrug strategy for combinatorial drug delivery, J Colloid Interface Sci, 417, 301, 10.1016/j.jcis.2013.11.061 · DOI
  147. Falcoz, 2002, Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers, J Clin Pharmacol, 42, 887, 10.1177/009127002401102803 · doi:10.1177/009127002401102803
  148. Vierling, 2003, Prodrugs of HIV protease inhibitors, Curr Pharm Des, 9, 1755, 10.2174/1381612033454441 · DOI
  149. Bimbo, 2010, Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats, ACS Nano, 4, 3023, 10.1021/nn901657w · DOI · Paper page
  150. Wang, 2010, Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs, Mol Pharmacol, 7, 227, 10.1021/mp900221e · DOI
  151. Kapoor, 2009, Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release, J Control Release, 140, 34, 10.1016/j.jconrel.2009.07.015 · doi:10.1016/j.jconrel.2009.07.015
  152. Zhang, 2011, Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties, Int J Pharm, 410, 118, 10.1016/j.ijpharm.2010.07.040 · DOI
  153. Cao, 2013, Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs, Eur J Pharm Sci, 48, 64, 10.1016/j.ejps.2012.10.012 · DOI
  154. Chen, 2012, Mesoporous silica nanoparticles with manipulated microstructures for drug delivery, Colloids Surf B Biointerfaces, 95, 274, 10.1016/j.colsurfb.2012.03.012 · DOI
  155. Korotcenkov, 2010, Silicon porosification: state of the art, Crit Rev Solid State Mater Sci, 35, 153, 10.1080/10408436.2010.495446 · doi:10.1080/10408436.2010.495446
  156. Xu, 2013, Mesoporous systems for poorly soluble drugs, Int J Pharm, 453, 181, 10.1016/j.ijpharm.2012.09.008 · DOI · Paper page

Cited by

See all 176

Metadata

Authors
B. Shekhawat, P., & B. Pokharkar, V.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2017-05
Volume
7
Issue
3
Pages
260-280
ISSN
2211-3835 (ISSN-L)
OpenAlex
W2547622589
Cited by
176
References
13
FWCI
7.56
Type
journal article
Language
en
Open access
gold
Licence
Funders
Women Scientist Scheme-A (SR/WOS-A/LS-248/2012)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. https://app.cochat.ai/papers/10.1016/j.apsb.2016.09.005
The paper
B. Shekhawat, P., & B. Pokharkar, V. (2017). Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2016.09.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.